Study
| Multicenter, open-label, multicohort phase 1/2 trial |
| Locally advanced or metastatic RET fusion-positive NSCLC |
| Pralsetinib (n=237) |
Efficacy
| ORR:78% [68-85] |
| mDoR: 13.4 mos [9.4-23.1] |
Safety
| Grade≥ 3: Neutropenia (19%), hypertension (11l%), lymphopenia (5%) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf
Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023
